Its lead candidate, leronlimab (PRO 140), belongs to a new class of therapeutics called viral-entry inhibitors, and is one of the most advanced experimental monoclonal antibodies for HIV treatment.

CytoDyn has partnered with Chinese company Longen China Group on the development of leronlimab as a potential treatment for the 2019 novel coronavirus and cancer.